Kiyoshi Nobori Selected Research

molidustat

4/2022	Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single-arm, open-label, phase 3 study.
12/2021	Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single-arm, phase 3 study.
10/2021	Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis.
1/2021	Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
1/2021	Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kiyoshi Nobori Research Topics

Disease

5	Anemia 04/2022 - 01/2021
4	Hypoxia (Hypoxemia) 12/2021 - 01/2021
3	Neoplasms (Cancer) 01/2022 - 12/2011
2	Neuroblastoma 01/2022 - 01/2019
2	Chronic Renal Insufficiency 01/2021 - 01/2021
2	Coronary Artery Disease (Coronary Atherosclerosis) 09/2013 - 02/2013
2	Cardiomegaly (Heart Hypertrophy) 04/2007 - 08/2002
1	Sarcoma (Soft Tissue Sarcoma) 01/2019
1	Inflammation (Inflammations) 02/2013
1	Necrosis 02/2013
1	Hypotension (Low Blood Pressure) 07/2012
1	Thrombosis (Thrombus) 07/2012
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2011
1	Heart Failure 01/2011
1	Infections 08/2003
1	Ischemia 08/2003
1	Hypertrophy 08/2002

Drug/Important Bio-Agent (IBA)

5	molidustatIBA 04/2022 - 01/2021
4	Prolyl-Hydroxylase InhibitorsIBA 12/2021 - 01/2021
3	HematinicsIBA 12/2021 - 01/2021
2	olaparibIBA 01/2022 - 01/2019
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 01/2019
2	Erythropoietin FDA Link 01/2021 - 01/2021
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 02/2013 - 01/2011
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 09/2013
1	Interleukin-6 (Interleukin 6)IBA 02/2013
1	Ezetimibe (Zetia)FDA Link 02/2013
1	LDL CholesterolIBA 02/2013
1	C-Reactive ProteinIBA 02/2013
1	PTX3 proteinIBA 02/2013
1	oxidized low density lipoproteinIBA 02/2013
1	erucylphosphocholineIBA 12/2011
1	Glucose (Dextrose)FDA LinkGeneric 12/2011
1	Angiotensin Receptor AntagonistsIBA 01/2011
1	Ribosomal Protein S6 Kinases (S6 Kinase)IBA 04/2007
1	NG-Nitroarginine Methyl Ester (L-NAME)IBA 08/2003
1	Cyclin AIBA 08/2003
1	Phosphotransferases (Kinase)IBA 08/2003
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 08/2003
1	Proteins (Proteins, Gene)FDA Link 08/2003
1	Cyclin D1IBA 08/2002

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 01/2019 - 12/2011
2	Therapeutics 12/2011 - 01/2011
1	Peritoneal Dialysis 04/2022
1	Renal Dialysis (Hemodialysis) 12/2021
1	Percutaneous Coronary Intervention 07/2012